Thursday, November 23, 2017
Orig3n, Inc., a Boston based biotech company pioneering the future of health through genetics and regenerative medicine research, today announced the acquisition of Interleukin Genetics CLIA laboratory and their remaining assets. Interleukin Genetics' technology will become a core component of Orig3n's DNA test business to empower more people to take charge of their health through genetic insights.
Interleukin Genetics brings exceptional and valuable assets to Orig3n, including a CLIA Certified Genetics Laboratory in Waltham, Massachusetts. The automated genotyping lab is fully licensed for testing in all 50 U.S. states and is capable of processing over one million samples per year. In addition to the company's state of the art technology and its HIPAA and HITECH compliance, Interleukin Genetics also brings its ILUSTRA™ Inflammation Management Program and its Inherent Health® genetic tests for nutritional needs, weight management, heart health, and bone health to Orig3n. All personalized genetic tests will be consolidated under the Orig3n brand.
"Once we met with Interleukin Genetics, we saw a natural alignment between the two organizations regarding our shared commitment to a future of personalized health," said Robin Y. Smith, CEO of Orig3n. "With our trajectory of accelerated growth, we couldn't imagine a better fit for acquisition. We are very pleased to be welcoming Interleukin Genetics to Orig3n."
Orig3n's regenerative medicine research lab will remain in Boston's Innovation District and the genetic testing will be consolidated to Interleukin Genetics' CLIA laboratory. Rene Oda, previously the Director of Technology at Interleukin Genetics will join Orig3n as the Director of Product Management and Dr. Lynn Doucette Stamm, joins as Senior Vice President of Development and Clinical Operations.
"We are looking forward to using our skillsets with Orig3n's to expand the array of direct to consumer DNA tests," said Dr. Lynn Doucette Stamm. "We see innovative growth opportunities ahead and we're very excited to be joining a company focused on furthering the common good and advancing the future of health through genetics and regenerative medicine research."
